Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results for the second quarter ended June 30, 2019, and recent business highlights.
Second Quarter 2019 Financial Highlights
Total net product revenues increased 38% to $26.2 million compared to $19.0 million in the second quarter of 2018;
Gross margin of 66% compared to gross margin of 59% in the second quarter of 2018;
Net loss of $19.8 million, or $0.45 per share, which includes the $17.5 million upfront license payment to MediWound for North American rights to NexoBrid®;
Non-GAAP adjusted net loss, excluding the $17.5 million upfront license payment to MediWound, of $2.3 million, or $0.05 per share, compared to a net loss of $4.7 million, or $0.12 per share, in the second quarter of 2018;
Non-GAAP adjusted EBITDA of $1.8 million compared to a loss of $1.4 million in the second quarter of 2018;
As of June 30, 2019, the company had $66.0 million in cash and short-term investments compared to $82.9 million as of December 31, 2018; and
Full year 2019 revenue guidance for MACI® and Epicel® raised to $112 to $116 million compared to previous full year revenue guidance of $110 million to $114 million.
Recent Business Highlights
During and since the second quarter of 2019, the company:
Reported record second quarter revenues, marking the ninth consecutive quarter with record revenues for the reported quarter and the highest Epicel revenue for a second quarter in history;
Deployed the expanded MACI sales force, which increased from 40 to 48 sales representatives and initiated a MACI sales force sizing assessment based on an expanded target audience of approximately 5,000 surgeons who perform a high volume of cartilage repair procedures;
Announced an exclusive license agreement with MediWound for North American rights to NexoBrid, a registration-stage biological orphan product for debridement of severe thermal burns;
Announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) has agreed to fund the NexoBrid expanded access treatment (NEXT) protocol; and
Confirmed plans after meeting with the U.S. Food and Drug Administration (FDA) to submit a Biologics License Application (BLA) for NexoBrid to the FDA in the second quarter of 2020.
“The continued strength in MACI revenue growth reflects the increasing number of surgeons who view MACI as the standard of care for certain large, full thickness cartilage defects,” said Nick Colangelo, president and CEO of Vericel. “Given the significant growth in new surgeons and biopsy volume, as well as the strength in Epicel demand, we have increased our revenue guidance for 2019. Looking forward, we anticipate submitting the NexoBrid BLA in the second quarter of 2020 which, upon FDA approval, would create a third growth driver for the company in 2021 and beyond.”
Second Quarter 2019 Results
Total net product revenues for the quarter ended June 30, 2019 increased 38% to $26.2 million compared to $19.0 million in the second quarter of 2018. Total net product revenues for the quarter included $20.8 million of MACI® (autologous cultured chondrocytes on porcine collagen membrane) net revenue and $5.3 million of Epicel® (cultured epidermal autografts) net revenue, compared to $14.1 million of MACI net revenue and $4.9 million of Epicel net revenue, respectively, in the second quarter of 2018.
Gross profit for the quarter ended June 30, 2019 was $17.1 million, or 66% of net revenues, compared to $11.3 million, or 59% of net revenues, for the second quarter of 2018.
Total operating expenses for the quarter ended June 30, 2019 were $37.3 million, including the $17.5 million upfront license payment to MediWound Ltd. for North American Rights to NexoBrid. Excluding the $17.5 million license payment, operating expenses were $19.8 million, compared to $15.5 million for the same period in 2018. The increase in operating expenses was primarily due to a $1.4 million increase in stock-based compensation, an incremental $0.7 million in MACI sales force expenses as a result of the sales force expansion in 2019, and a $0.9 million increase in selling expenses and patient reimbursement support services.
Vericel’s net loss for the quarter ended June 30, 2019, which includes the $17.5 million upfront license payment for NexoBrid, was $19.8 million, or $0.45 per share. Non-GAAP adjusted net loss, excluding the $17.5 million upfront license payment for NexoBrid, was $2.3 million, or $0.05 per share, compared to a net loss of $4.7 million, or $0.12 per share, for the second quarter of 2018. See table reconciling non-GAAP measures for more details.
Non-GAAP adjusted EBITDA was $1.8 million for the quarter ended June 30, 2019 compared to a loss of $1.4 million in the second quarter of 2018. See table reconciling non-GAAP measures for more details.
As of June 30, 2019, the company had $66.0 million in cash and short-term investments compared to $82.9 million as of December 31, 2018.
Full Year 2019 Financial Guidance
The company now expects total MACI and Epicel net product revenues for the full year 2019 to be in the range of $112 to $116 million, compared to the previous full year revenue guidance of $110 to $114 million.
Good luck!
Hard to read as overall market reaction to Trump/China spat affected vcel as well.
Lots of positive views in Zacks er al.
Before bell earnings followed the very next day with a conference?
We’ll see.
I fear that even with a good report the overall market jitters will be the proverbial wet blanket.
Vericel to Present at the 39th Annual Canaccord Genuity Growth Conference on Thursday, August 8, 2019
8:00 AM ET 8/1/19 | GlobeNewswire
Vericel to Present at the 39th Annual Canaccord Genuity Growth Conference on Thursday, August 8, 2019
CAMBRIDGE, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 39(th) Annual Canaccord Genuity Growth Conference in Boston, Massachusetts on Thursday, August 8, 2019 at 12:00pm Eastern Time.
A live webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com
About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI(R) (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel(R) (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American commercial rights to NexoBrid(R) , a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company's website at www.vcel.com.
Epicel(R) and MACI(R) are registered trademarks of Vericel Corporation. NexoBrid(R) is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. (c) 2019 Vericel Corporation. All rights reserved.
Did The Underlying Business Drive Vericel's (NASDAQ:VCEL) Lovely 767% Share Price Gain?
We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many investors. You won't get it right every time, but when you do, the returns can be truly splendid. One bright shining star stock has been Vericel Corporation (NASDAQ:VCEL), which is 767% higher than three years ago. Unfortunately, though, the stock has dropped 5.8% over a week. But this could be related to the soft market, with stocks selling off around 0.9% in the last week.
It really delights us to see such great share price performance for investors.
Check out our latest analysis for Vericel
Vericel isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.
In the last 3 years Vericel saw its revenue grow at 22% per year. That's much better than most loss-making companies. And it's not just the revenue that is taking off. The share price is up 105% per year in that time. It's always tempting to take profits after a share price gain like that, but high-growth companies like Vericel can sometimes sustain strong growth for many years. In fact, it might be time to put it on your watchlist, if you're not already familiar with the stock.
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).
We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. So it makes a lot of sense to check out what analysts think Vericel will earn in the future (free profit forecasts).
A Different Perspective
It's nice to see that Vericel shareholders have received a total shareholder return of 78% over the last year. That gain is better than the annual TSR over five years, which is 41%. Therefore it seems like sentiment around the company has been positive lately. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. If you want to research this stock further, the data on insider buying is an obvious place to start. You can click here to see who has been buying shares - and the price they paid.
Oppenheimer is an interesting case-
I have to look more into their performance history regarding their calls.
As far as institutional ownership is concerned, if they’re buying, great! Often signifies stability or growth.
Here’s a real good article on pros/cons of institutional ownership
https://www.investopedia.com/articles/stocks/07/insitutional-owners.asp
Best of luck to you and us all!
Tv, thanks for summary. I wonder why Oppenheimer is so far off the average ? Also, I am curious on your thoughts of the approx. 86% inst. ownership? I view this as good thing, I hope I am right. I have been along a long time . Thanks
Yeah, a few articles mention that.
Interesting
funny your posts keep picking up Oppenheimer eye catching target price on 2U from $83.00 to $67.00
2U which is $TWOU. $TWOU is down 36% in pre-market today to $23.34
hopefully that isn't a bad omen for Vericel
Zacks Investment Research upgraded shares of Vericel (NASDAQ:VCEL) from a hold rating to a buy rating in a research report report published on Tuesday, Zacks.com reports. The firm currently has $22.00 target price on the biotechnology company’s stock.
According to Zacks, “Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the knee, and Epicel (R) for the treatment of severe burns. It is also developing MACI (TM) for the treatment of cartilage defects in the knee, and ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. Vericel Corporation, formerly Aastrom Biosciences, Inc., is based in United States. “
Get Vericel alerts:
Several other analysts also recently weighed in on VCEL. BidaskClub downgraded YY from a sell rating to a strong sell rating in a research note on Tuesday, July 23rd. Oppenheimer decreased their target price on 2U from $83.00 to $67.00 and set an outperform rating for the company in a research note on Wednesday, May 8th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $22.98.
Shares of NASDAQ:VCEL opened at $19.42 on Tuesday. The firm’s 50 day simple moving average is $18.46. Vericel has a twelve month low of $9.70 and a twelve month high of $21.00. The company has a market cap of $852.75 million, a P/E ratio of -138.71 and a beta of 2.84. The company has a debt-to-equity ratio of 0.24, a quick ratio of 8.16 and a current ratio of 8.47
analyst's Expect Vericel Corp (NASDAQ:VCEL) Will Announce Quarterly Sales of $24.30 Million
Tuesday, July 30th, 2019
Ned Boundy
Equities analysts predict that Vericel Corp (NASDAQ:VCEL) will post sales of $24.30 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Vericel’s earnings, with the highest sales estimate coming in at $24.50 million and the lowest estimate coming in at $24.10 million. Vericel reported sales of $19.01 million during the same quarter last year, which indicates a positive year-over-year growth rate of 27.8%. The company is expected to report its next earnings results on Monday, August 5th.
According to Zacks, analysts expect that Vericel will report full-year sales of $113.69 million for the current year, with estimates ranging from $113.48 million to $113.90 million. For the next fiscal year, analysts forecast that the company will post sales of $146.18 million, with estimates ranging from $141.85 million to $150.50 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Vericel.
Vericel (NASDAQ:VCEL) last announced its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.07). Vericel had a negative net margin of 3.51% and a negative return on equity of 3.40%. The firm had revenue of $21.81 million for the quarter, compared to the consensus estimate of $22.51 million. During the same period in the prior year, the firm posted ($0.21) earnings per share. The company’s revenue for the quarter was up 21.0% on a year-over-year basis.
A number of equities research analysts have recently issued reports on VCEL shares. Oppenheimer lowered their price target on shares of 2U from $83.00 to $67.00 and set an “outperform” rating on the stock in a report on Wednesday, May 8th. Zacks Investment Research downgraded shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 11th. Finally, BidaskClub raised shares of Xilinx from a “hold” rating to a “buy” rating in a research note on Saturday, June 29th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $22.98.
In other Vericel news, Director Steven C. Gilman sold 7,500 shares of the stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $16.81, for a total transaction of $126,075.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Gerard J. Michel sold 17,500 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $15.62, for a total transaction of $273,350.00. Following the transaction, the chief financial officer now owns 131,422 shares in the company, valued at $2,052,811.64. The disclosure for this sale can be found here. Insiders sold 42,500 shares of company stock worth $697,275 over the last ninety days. 4.50% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of VCEL. Advisory Services Network LLC grew its position in Vericel by 1,400.0% during the first quarter. Advisory Services Network LLC now owns 1,500 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 1,400 shares during the last quarter. Pearl River Capital LLC bought a new position in Vericel during the first quarter valued at approximately $72,000. Great West Life Assurance Co. Can bought a new position in Vericel during the fourth quarter valued at approximately $78,000. SG Americas Securities LLC bought a new position in Vericel during the first quarter valued at approximately $109,000. Finally, First Quadrant L P CA bought a new position in Vericel during the first quarter valued at approximately $115,000. Institutional investors and hedge funds own 85.16% of the company’s stock.
Shares of Vericel stock traded down $0.30 on Friday, reaching $19.53. The stock had a trading volume of 5,061 shares, compared to its average volume of 489,178. Vericel has a 1 year low of $8.95 and a 1 year high of $21.00. The stock has a market capitalization of $862.83 million, a P/E ratio of -140.36 and a beta of 2.84. The company has a current ratio of 8.47, a quick ratio of 8.16 and a debt-to-equity ratio of 0.24. The stock’s 50 day moving average price is $17.26.
“Growing number” seeking alternatives
For those with cartilage damage, new treatments are also emerging. “There are newer agents that we can use to inject into the hip and knee that may be safer for alleviating pain, with little to no risk for complications,” says Dr. Bhatia.
This includes a technique that uses matrix-induced autologous chondrocyte implantation (MACI) to restore knee cartilage. According to Dr. Bhatia, the first step in MACI involves taking a sample of the patient’s cartilage from a non-weight-bearing part of the knee. The tissue is sent to a lab, where cells are embedded in a special collagen membrane that promotes tissue growth. During surgery, the new tissue, called the MACI membrane, is trimmed to the desired size and shape, and secured to the bone.
Stay Active, Longer
As the number of joint replacement surgeries continues to grow, Northwestern Medicine Hip and Knee Joint Preservation Center at Central DuPage Hospital is serving a growing number of patients seeking alternative options. “Joint replacement produces outstanding results for people,” says Dr. Bhatia. “But if we can help individuals avoid joint replacement, or delay it, it helps keep them more active in their life. That’s what we’re trying to achieve.”
https://www.nm.org/healthbeat/medical-advances/new-therapies-and-drug-trials/what-you-need-to-know-about-protecting-your-joints
Vericel to Report Second-Quarter 2019 Financial Results on August 6, 2019
Date : 07/23/2019 @ 8:00AM
Estimate of -.46 loss including one time items.
Now slowwwwly chipping away at more LODs
17’s not far?
Low volume- maybe just markets being made.
But ugh! Nonetheless
sentiments?
pretty quiet here.
have been out for a bit, but saw the resurgence to near 20-
now back in 18's.
thoughts?
Global $25.4 Bn Tissue Engineering (Technologies and Therapeutic) Markets, 2015-2018 & 2019-2024: Orthopedics, Musculoskeletal & Spine Applications Corner the Largest Share GlobeNewswire July 02, 2019
Dublin, July 02, 2019 (GLOBE NEWSWIRE) -- The "Tissue Engineering: Technologies and Therapeutic Areas - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering.
Overall, the Tissue Engineering market, globally, for 2019 is projected to touch US$25.4 billion.
Organs developed using Tissue Engineering are highly durable and efficient, with applications gaining ground in areas, such as surgical manipulation of tissues and prosthetics for cardiac, cancer and orthopedic uses. The technology has reached a stage where the products offer a reduced rate of rejection by the body, which would further propel the market for Tissue Engineering. Though North America is the leading global region for revenues garnered from Tissue Engineering, Asia-Pacific is likely to outpace all other regions by posting the fastest CAGR over the analysis period.
2. KEY MARKET TRENDS
2.1 Latest Developments in Tissue Engineering
...
2.6 Plasma Protein Shows Promise for Making Wound-Healing Tissue Scaffolds
2.7 Speed of Bone Repair Process May be Accelerated with the Help of Two Types of Cells
2.8 New Therapy Developed for Osteomyelitis
...
2.12 Patients with Cartilage Defects Get the Boon of Cartilage Tissue Engineering
3. KEY GLOBAL PLAYERS
.....
Vericel Corporation (United States)
4. KEY BUSINESS AND PRODUCT TRENDS
....
Vericel Corporation and Innovative Cellular Therapeutics Co., Ltd. Join Forces on Advanced Cell Therapy Portfolio
....
Vericel Highlights MACI Implant for Treating Articular Cartilage Defects in the Knee at AOSSM 2017 Meeting
6. NORTH AMERICA
Major Market Players
...
Vericel Corporation (United States)
https://www.researchandmarkets.com/reports/4790912/tissue-engineering-technologies-and-therapeutic?utm_source=GNDIY&utm_medium=PressRelease&utm_code=wbn66b&utm_campaign=1271892+-+Global+%2425.4+Bn+Tissue+Engineering+(Technologies+and+Therapeutic)+Markets%2c+2015-2018+%26+2019-2024%3a+Orthopedics%2c+Musculoskeletal+%26+Spine+Applications+Corner+the+Largest+Share&utm_exec=chdo54prd
Tissue Engineering: Technologies and Therapeutic Areas – A Global Market Overview
ID: 4790912 Report June 2019 Region: Global 374 Pages Industry Experts
DESCRIPTION
TABLE OF CONTENTS
SAMPLES
COMPANIES MENTIONED
METHODOLOGY
OPTIONS
FEATURED COMPANIES
Acelity L.P. Inc.
Baxter International Inc.
Cerapedics, Inc.
Depuy Synthes
Mesoblast Ltd
RTI Surgical®
MORE
PRINTER FRIENDLY
SEND TO A FRIEND
Organs developed using Tissue Engineering are highly durable and efficient, with applications gaining ground in areas, such as surgical manipulation of tissues and prosthetics for cardiac, cancer and orthopedic uses. The technology has reached a stage where the products offer a reduced rate of rejection by the body, which would further propel the market for Tissue Engineering. Though North America is the leading global region for revenues garnered from Tissue Engineering, Asia-Pacific is likely to outpace all other regions by posting the fastest CAGR over the analysis period.
Orthopedics, Musculoskeletal & Spine applications corner the largest share of the global market for Tissue Engineering in terms of application, which is estimated at 60.5% or US$13.5 billion in 2018 and is projected to reach US$34.7 billion by 2024 at a CAGR of 17.1% between the two years. Overall, the Tissue Engineering market, globally, for 2019 is projected to touch US$25.4 billion.
Research Findings & Coverage
The global market for Tissue Engineering analyzed in this report with respect to Material Types and Applications
The study explores the aforementioned categories of Tissue Engineering in each major region/country worldwide for the analysis period
Biomaterials for Tissue Engineering Get Innovative
Successful Creation of Functioning Kidney Tissue by Researchers
Human Trials of Novel Tissue-Engineered Blood Vessel Replacements Now Closer
Plasma Protein Shows Promise for Making Wound-Healing Tissue Scaffolds
Key business trends focusing on product innovations/developments, M&As, JVs, and other recent industry developments
Major companies profiled - 38
The industry guide includes the contact details for 270 companies
Product Outline
The report analyzes the market for the following material types of Tissue Engineering including:
Biomimetic Materials
Composite Materials
Nanocomposite Materials
Nanofibrous Materials
The market for applications of Tissue Engineering explored in this report includes:
Cancer
Cardiology & Vascular
Dental/Oral
Neurology
Orthopedics, Musculoskeletal & Spine
Skin/Integumentary
Others
Analysis Period, Units and Growth Rates
The report reviews analyze and project the global Tissue Engineering market for the period 2015-2024 in terms of US$ and the compound annual growth rates (CAGRs) projected from 2018 through 2024
Geographic Coverage
North America (The United States, Canada, and Mexico)
Europe (France, Germany, Italy, The United Kingdom and Rest of Europe)
Asia-Pacific (China, India, Japan, South Korea and Rest of Asia-Pacific)
South America (Argentina, Brazil and Rest of SA)
Rest of World
Vericel Corp (NASDAQ:VCEL) – Research analysts at Oppenheimer lowered their Q2 2019 earnings estimates for Vericel in a research report issued to clients and investors on Monday, June 24th. Oppenheimer analyst K. Degeeter now anticipates that the biotechnology company will post earnings per share of ($0.46) for the quarter, down from their prior forecast of ($0.06). Oppenheimer has a “Outperform” rating and a $32.00 price objective on the stock. Oppenheimer also issued estimates for Vericel’s FY2019 earnings at ($0.30) EPS.
Bill Gunderson
@billgunderson
President of Gunderson Capital Mgt. Host of nationally syndicated Best Stocks Now Radio Hour. Inventor of Best Stocks Now app. Fox CNBC Marketwatch & TheStreet.
Bill Gunderson
? @billgunderson
4m4 minutes ago
Chart of the day so far. $VCEL I am long in my Emerging Growth Portfolio.
Chart of the day so far. $VCEL I am long in my Emerging Growth Portfolio.
— Bill Gunderson (@billgunderson) June 26, 2019
nice start to the day!
gaining back some lost ground.
Untrue, but I certainly do voice myself when things look bad or don’t seem to have rhyme nor reason.
Posts are rarely negative at that. I refrain from bashing, whether that be posters or the company as best I can.
Like us all, While i come from an outside perspective, I do question perceptions- in my world, perception is truth.
Plus, I’m superstitious enough not to jinx things when they appear to be on the upswing!
That said, I follow plenty of stocks and often enough, this one defies much logic at times.
Here’s to hoping we reach that and more- soon.
The upward momentum seems to have hit a wall today.
Would hate to see another elevator down move.
they are accounting for the charge on that burn unit product license
also
In a research note revealed on Thursday morning, The Buy rating of Vericel Corp (NASDAQ:VCEL) shares was reiterated at BTIG, who now has a $24 target on the stock
Hi Realfast95. I think that estimate of 0,47 for the 2Q is the best so far in historical terms.
Vericel Corp (NASDAQ:VCEL) – Svb Leerink cut their Q2 2019 EPS estimates for Vericel in a research note issued to investors on Wednesday, June 19th. Svb Leerink analyst D. Antalffy now expects that the biotechnology company will post earnings of ($0.47) per share for the quarter, down from their previous forecast of ($0.08). Svb Leerink also issued estimates for Vericel’s Q3 2019 earnings at $0.00 EPS, FY2019 earnings at ($0.34) EPS, Q1 2020 earnings at ($0.04) EPS and FY2020 earnings at $0.26 EPS.
partner article, Vericel mentioned
https://news.alphastreet.com/mediwound-stock-plunges-to-a-record-low-on-gloomy-future/
Dan Orlando's new gig
Alcresta Therapeutics Announces Appointment of Daniel Orlando as Chief Executive Officer
https://www.businesswire.com/news/home/20190617005118/en/Alcresta-Therapeutics-Announces-Appointment-Daniel-Orlando-Chief
Alcresta Therapeutics, Inc. is dedicated to developing and commercializing novel, enzyme-based products designed to address challenges faced by patients living with gastrointestinal disorders and rare diseases. Alcresta currently markets RELiZORB for enterally fed patients with pancreatic insufficiency, which occurs in cystic fibrosis, pancreatic cancer and pancreatitis, and is developing platform applications for patients with short bowel syndrome (SBS) and prematurely born infants treated in the NICU. Alcresta Therapeutics, Inc. is backed by top-tier investors: Athyrium Capital Management, Bessemer Venture Partners, HealthQuest Capital, Frazier Healthcare Partners, and Third Rock Ventures
WVU orthopedic surgeons offer cartilage repair procedure
(I corrected their spelling)
https://www.wvnews.com/wvumedicine/wvu-orthopaedic-surgeons-offer-cartilage-repair-procedure/article_cca3e436-8e0a-11e9-af37-5b1581bf59ef.html
MORGANTOWN — Orthopedic surgeons at WVU Medicine are now offering a procedure for the treatment of full thickness cartilage defects of the knee.
Matrix-impregnated autologous chondrocyte implantation, known as MACI, provides surgeons with a technically improved way to rebuild damaged and missing cartilage. WVU Medicine J.W. Ruby Memorial Hospital is the only hospital in the state to offer this procedure.
“With this procedure, we are able to repair defects to the cartilage of the knee before they progress and develop into osteoarthritis, which is more difficult to treat,” said Barry McDonough, M.D., WVU Medicine orthopedic surgeon.
In the two-stage procedure, surgeons perform a biopsy of healthy cartilage tissue from a non-weight bearing area of the knee to be sent to the Vericel lab, where chondrocytes, the building blocks of cartilage, are extracted and grown on a collagen matrix.
The prepared matrix is then sent to the surgeon, who implants it into the knee to completely fill the defect.
“In the past, procedures to repair damaged cartilage were lengthy and technically difficult,” McDonough said. “Surgeons were required to stitch a matrix in place and inject the cartilage-forming chondrocytes under it, which was time-consuming. This procedure, however, uses improved tools that simplify the process and eliminate the need for stitches to hold the implant in place.”
This procedure is appropriate for patients ages 18 to 55 who have cartilage defects due to trauma and is not available as a treatment for arthritic knee pain.
Patients can expect to return to full weight bearing six-to-eight weeks after the procedure and may require a recovery period of nine months or longer before returning to high-impact athletic activity.
But of course
Expect anything less?
Would sure be nice to see insides but for a change- not just cash in cheap shares and flip.
Actually Put some of their own skin in the game vs ripping our skin off for $erious profit.
right on schedule - CFO planned sale on 6/10
From the article
"Ryan Zimmerman, an analyst who follows Vericel for the financial services firm BTIG in Chicago, said the new procedure has become the gold standard for cartilage repair. About 900 of the 3,000 sports medicine surgeons in the United States have learned how to use it."
fair enough EOM
If you look at the last 2 years, you will see we've had multiple drops like this before...they've all turned out to be great buying opportunities. Nothing about this one seems any different to me.
holy cannoli!
well-
all bets were off under 15.80ish....
where do we stand now that it's plummeted into the 14's again?
man this is brutal.
maybe other posters will crawl out from under their collective rocks to say how wonderful this all is!
man, I miss pumpers!
Great and positive article
Now here’s hoping they’re right and things head north sooner than later
new seeking alpha article
https://seekingalpha.com/article/4269386-target-acquired-nexobrid-acquisition-implications-vericel
Target Acquired: The NexoBrid Acquisition And Its Implications For Vericel
Jun. 10, 2019 8:41 AM ET |
About: Vericel Corporation (VCEL), Includes: MDWD
Summary
Vericel's newly acquired burn care product, NexoBrid, is revolutionary, creating a "new paradigm" in burn care.
NexoBrid will not immediately add to Vericel's top line revenue, but its long-term impact will be substantial.
The NexoBrid purchase also adds stability via diversification of product line; Vericel is now a "three-trick pony."
A second acquisition in 2019 is a possibility.
Technically, the market downturn and industry rotation has weighed on VCEL, and it is attempting to recover from a bearish breakout of a head and shoulders top.
For a year, Vericel (VCEL) teased investors with hints that it would be adding an acquisition to its product line. After doing a large, surprise secondary offering of $75 million in June 2018, Vericel indicated it was actively on the hunt for "commercial products or businesses which would be... complementary to Vericel's existing commercial franchises or its advanced cell therapy platform..." And then, the wait began.
I wrote an article that June, speculating on acquisition targets and boldly asserting in Victorian era diction that a product acquisition was "nigh," and then a quarter passed. And then another, and another. Investors, most especially myself, were left wondering, "Where's the beef?" (If you are too young to understand this reference, 1) I envy you, and 2) here it is.)
Finally, at long last and nearly a year later, on May 7, 2019, Vericel delivered on its promise, acquiring North American rights for commercial sales of the breakthrough burn treatment product, NexoBrid.
Investment Thesis
The NexoBrid acquisition was worth the wait. It is a disruptive breakthrough in burn care therapy, it will add at least 90 million to Vericel's revenue stream, and its addition builds the burn care side of the company and provides balance to what currently is a MACI-dominated product portfolio.
NexoBrid: Enzymatic magic in a bottle
The Acquisition: NexoBrid, A "New Paradigm" In Burn Care
Vericel has acquired exclusive North American sales rights to revolutionary burn-wound debridement agent, NexoBrid. Debridement is the process of removing the dead layer of tissue on the surface of a severe burn. This dead tissue must be removed to avoid infection and to make way for skin transplant (Vericel's own Epicel or other type of graft) and/or to promote natural healing. The traditional method of debridement is via surgery with a scalpel, a process that is laborious for the doctor and painful for the patient. In addition, some healthy tissue is often unavoidably removed during the process. NexoBrid truly revolutionizes this process. It is a biological product made up of proteolytic enzymes that provides three vast improvements to the debridement process:
The procedure is very easy for the doctor and vastly less painful for the patient. After application and the appropriate wait time, the dissolved eschar is simply gently scraped off with a tongue depressor or similar device.
It is fast. The NexoBrid solution is applied and dissolves the eschar (dead tissue) within four hours, and one doctor can treat many patients in parallel, particularly important during major burn catastrophes when multiple victims suffer burns simultaneously.
The enzymes do not react with healthy skin tissue, so adjacent healthy tissue is unharmed.
One does not need to be a doctor to see how tremendously beneficial this product is for the treatment of severe burns.
The CEO is "Delighted" About The Acquisition
In the May 2019 Q1 earnings call, Vericel's CEO Nick Colangelo gave a detailed and exulted rationale for the NexoBrid acquisition, praising the product with phrases such as "high value," "highly innovative," "highly synergistic," and "paradigm shift[ing]." Sounds like a CEO who is happy with his purchase.
I encourage you to read the entire Q1 transcript, but in the meantime, here are a few highlights from Colangelo's "How do I love thee? Let me count the ways" NexoBrid pronouncement. Note the italicized superlatives:
We are delighted to expand our burn care franchise with the addition of NexoBrid, a highly innovative biological organ product..., which we believe represents a paradigm shift in the standard of care for hospitalized burn patients. This is a high value product in an area of significant unmet need...
NexoBrid also is highly synergistic with our existing commercial franchise and will significantly expand Vericel’s presence in the burn care market...
[it] also will have a pull through effect to further increase Epicel penetration...
...we believe this transaction is very attractive from a financial perspective..., thereby significantly enhancing the long-term growth profile of the company.
Colangelo is clearly excited about the NexoBrid acquisition and its future financial impact on the company, and based upon his ability to deliver value to shareholders - VCEL stock is up over 400% since he took over in 2014 - I am excited, too.
Timeline
NexoBrid is currently in Phase 3 trials in the US. According to parent company MediWound's (MDWD) Chairman, Steve Wills, submission for approval will take place "towards the end of the year [2019]," and expected commercial approval for usage in the US is anticipated to be between late 2020 and early 2021. Approval definitely appears to be a when, not an if; in the Q1 earnings call, Colangelo called NexoBrid a "de-risked asset," as it is "approved in the EU and other international markets," and it "generated positive top line results in the pivotal U.S. Phase 3 DETECT study."
Effect On The Balance Sheet
NexoBrid sales in North America should commence mid-year 2021. Allowing Vericel's salesforce a couple of years to disseminate the product into hospitals and burn care centers, I estimate that by 2023 NexoBrid sales will add at least $90 million in revenue annually to the top line of Vericel's balance sheet. Here is how I got to that figure, drawing data from the Q1 2019 earnings call:
Vericel estimates NexoBrid's total addressable market to be $200 million annually. If we speculate that NexoBrid captures 50% of the annual TAM, which seems very doable in a couple of years after sales launch due to the product's vast superiority to current debridement methods, that would give Vericel an additional $100 million in added revenue per year, minus around 10% for royalties to MediWound, which equals $90 million per year.
Vericel's guidance for the full year 2019 revenue is only $114 million. So, NexoBrid sales, once ramped up, will nearly double the company's current revenue.
Backing away from the math, the bottom line is that NexoBrid will add a lot to the top line, but we need to be patient for a couple of years for the product to be approved and for Vericel's sales team to get the word out.
Note that Epicel, Vericel's other burn care product (autologous lab-grown skin) is a high margin but small niche product; it is appropriate for only 2% of hospitalized burn patients (those with burns greater than 40%), which amounts to only 600 patients per year in the US. NexoBrid, on the other hand, has an annual TAM of 30,000 patients, or 75% of the approximately 40,000 U.S. burn patients each year. NexoBrid's TAM is dramatically larger than Epicel's.
Why Didn't The Acquisition Move The Stock Price?
Mr. Market was thoroughly unimpressed with the acquisition, and the stock price has in fact trended down since the May 7 announcement. Why didn't the NexoBrid acquisition announcement move the stock price? In my opinion:
Many people didn't (and still don't) know what NexoBrid is and why it is such a revolutionary product.
It will not immediately add to Vericel's commercial sales, and investors are notoriously shortsighted.
The amount of revenue that NexoBrid will add to Vericel's top line is not yet very clear.
Vericel bought the North American sales rights, and NexoBrid is not yet approved for sale in North America.
The general market began correcting in early May, pulling all boats down with the receding tide.
I do expect the NexoBrid North American approval announcement to give the stock price a significant boost, but keep in mind that this will be 1-1.5 years from now.
Terms Of The Deal
Vericel has procured exclusive rights to NexoBrid revenue in North America. Here are the terms
Vericel paid parent company MediWound $17.5 million upfront.
Vericel will pay an additional $7.5 million when NexoBrid receives U.S. FDA approval (it currently has orphan status).
Vericel will pay tiered high single-digit to low double-digit royalties on net sales.
Vericel will also pay up to $125 million to MediWound contingent upon annual sales milestones
MediWound will also receive a split of gross profits on BARDA orders and a double-digit royalty on future BARDA purchases.
The Technical Analysis Crystal Ball
Pappy will guide us, although perhaps gold miner's tales cannot always be trusted...
VCEL is off its February 2019 $21 high by about 35%. No way to sugar coat a 35% decline - the last few months have been brutal for VCEL. But, let's not stare at the trees and lose sight of the forest. Here is the 5-year VCEL chart, and I think we can agree that despite the recent pullback, long-term price performance has been impressive:
Source: Seeking Alpha.com
Looking backward doesn't pay the bills, however, so let's look for patterns indicating VCEL's future direction. Below is the one-year chart (blue vertical lines mark quarterly earnings releases). Take a look, and then I will discuss what we see:
Source: StockCharts.com
Over the past six months, VCEL formed a head and shoulder's top formation (although technically flawed because the right shoulder does not slump lower than the left). It broke out to the downside in mid-May, then bounced off support at $15, retested the neckline at $17, and is now bouncing between the neckline and support like a ping pong ball.
We are at a wait and see moment. We want to see support at $15 hold and a retest and strong push through the neckline and the 50-day moving average above $17. Although Vericel zealots could attempt to buy low with a limit order near $15, I think VCEL is a "HOLD" right now; we wait until VCEL makes a strong close above the neckline and 50-day average to initiate a new purchase, and if the price plummets through $15 on above-average volume, then we consider reducing shares. I am guessing $15 holds and VCEL pushes through the 50-day average to the upside, but this is not a guessing game, and because the macro-environment is so dicey (trade war x 2), the prudent move is to hold until we have a clear sense of direction.
Final Thoughts
I am excited about the NexoBrid acquisition. Long term, which is the lens I am looking at Vericel through, it will add substantial revenue and make the company more balanced. Right now, about two-thirds of Vericel's revenue is generated by MACI. NexoBrid will build the burn care side of the company, both with direct added revenue and via stimulating additional Epicel sales via a "pull-through" effect. Furthermore, as a three-product company now, Vericel is less prone to implosion, should a competitor build a "better mousetrap" and render one of its products obsolete. And, let's not forget that with $84 million in cash even after the NexoBrid purchase, it is possible that Vericel might acquire another product in 2019. Fingers crossed that it is RECELL, the innovative burn care product made by Avita Medical (OTCQX:AVMXY).
Most BioTechs are down today...
Hopefully it isn't Daniel Orlando dumping his shares on the way out the door.
No blocks of 10,000 or more, have occurred today. So it feels like market makers walking it down.
Man this thing is frustrating
Again, seemed recently like some sort of footing was reestablished and today down nearly 7% and over a full dollar.
Ooofff
On May 28, 2019, Daniel Orlando notified the Company of his intention to resign as the Company’s Chief Operating Officer in order to join a privately held biotechnology company as its Chief Executive Officer . The effective date of Mr. Orlando’s resignation is June 14, 2019.
(c)
On June 3, 2019, the Company appointed Michael Halpin, 58, as Chief Operating Officer of the Company, effective as of June 15, 2019. Mr. Halpin joined the Company on April 10, 2017 as Senior Vice President, Quality and Regulatory Affairs, where he was responsible for quality activities and regulatory strategy. From 2016 until joining the Company, Mr. Halpin served as Vice President, North American region regulatory head at Sanofi Genzyme. Prior to that, Mr. Halpin served as Vice President, Regulatory Affairs for Genzyme’s biosurgery division, with regulatory oversight of all biosurgery and cell and gene therapy products, including Epicel ® and MACI ® . Prior to Genzyme, Mr. Halpin held a number of regulatory, quality and clinical affairs positions at several medical device companies, including Abbott/MediSense, C.R. Bard and Abiomed. Mr. Halpin received his master’s degree in biomedical engineering and bachelor’s degree in biochemistry from the University of Virginia.
There is no arrangement or understanding with any other person pursuant to which Mr. Halpin was appointed as the Chief Operating Officer, and there are no family relationships between Mr. Halpin and any director or executive officer of the Company. Additionally, there are no transactions involving Mr. Halpin that would be required to be reported under Item 404(a) of Regulation S-K.
Q2 2019 Earnings Forecast for Vericel Corp (VCEL) Issued By Oppenheimer
Posted by Philip Parker on Jun 3rd, 2019 // Comments off
Vericel logo
Vericel Corp (NASDAQ:VCEL) – Stock analysts at Oppenheimer reduced their Q2 2019 earnings per share (EPS) estimates for shares of Vericel in a research report issued on Wednesday, May 29th. Oppenheimer analyst K. Degeeter now expects that the biotechnology company will earn ($0.06) per share for the quarter, down from their prior forecast of ($0.04). Oppenheimer currently has a “Outperform” rating and a $32.00 target price on the stock. Oppenheimer also issued estimates for Vericel’s Q4 2019 earnings at $0.22 EPS, FY2019 earnings at $0.10 EPS, FY2020 earnings at $0.53 EPS, FY2021 earnings at $0.94 EPS, FY2022 earnings at $1.79 EPS and FY2023 earnings at $2.07 EPS.
https://www.baseballdailydigest.com/news/2019/06/03/q2-2019-earnings-forecast-for-vericel-corp-vcel-issued-by-oppenheimer.html
$VCEL - Potential new patient
(okay, bad taste, but it's not like it was an accident)
https://www.dailymail.co.uk/news/article-7083457/Man-sets-fire-seen-engulfed-flames-near-White-House.html
Man sets himself on fire on lawn near the White House as shocking video shows him being engulfed in flames
pic's inside
CAMBRIDGE, Mass., May 29, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) has agreed to fund the NexoBrid® expanded access treatment (NEXT) protocol. The NEXT protocol is being conducted under the U.S. Food and Drug Administration’s (FDA) expanded access program, which allows access to investigational products to treat patients with serious or immediately life-threatening diseases or conditions outside of clinical trials when no comparable or satisfactory alternative treatment options are available. U.S. burn surgeons participating in the NEXT protocol will be able to treat up to 150 patients during the preparation and review of the NexoBrid Biologics License Application (BLA).
On May 7, 2019, Vericel announced that it had entered into exclusive license and supply agreements with MediWound Ltd. to commercialize NexoBrid in North America. NexoBrid is a topically-administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial- and full-thickness thermal burns within four hours of application without harming viable tissue. MediWound will receive the additional funding from BARDA under an amendment to an existing BARDA contract. Under the terms of the License Agreement, MediWound will continue to conduct all development activities under the supervision of a Central Steering Committee comprised of members of each party until the BLA is approved and subsequently transferred to Vericel.
The NEXT protocol is an open-label, single-arm treatment protocol which allows for the treatment of up to 150 burn patients with deep partial- and full-thickness thermal burns up to 30% of total body surface area. Up to 30 sites will participate in the NEXT protocol. The protocol has been designed to be consistent with current real-life burn treatment practices in the U.S. The increased number of burn centers trained and familiar with NexoBrid prior to FDA approval and commercial availability will improve national readiness for potential burn mass casualty events. To further promote national readiness, the FDA has agreed that in the event of a burn mass casualty event that is not a nationally declared emergency, additional patients could be treated under the NEXT treatment protocol.
“We are very pleased with BARDA’s commitment to make NexoBrid available to patients under an expanded access protocol,” said Nick Colangelo, president and CEO of Vericel. “It is a reflection of the significant need for improved burn treatments and the compelling body of clinical data supporting the use of NexoBrid. The NEXT protocol will further extend the number of NexoBrid-trained physicians and healthcare providers in the United States and generate additional awareness, advocacy, and use at U.S. centers of excellence prior to commercialization of NexoBrid.”
Texas baby born without skin opens eyes for first time after biggest surgery yet
(The baby's status updated Sunday 5/26)
https://abc7news.com/science/texas-baby-born-without-skin-opens-eyes-for-first-time/5318038/
Sunday, May 26, 2019 6:14PM
HOUSTON, Texas -- At five months old, Ja'bari Gray is steadily gaining weight, weaning off pain medications and is now recovering from his biggest surgery yet.
"The doctors in San Antonio, where he was born, didn't know how to treat him, and said he wouldn't make it," said his mother, Priscilla Gray.
For the past week, technicians in Boston have been using a biopsy from Ja'bari's skin to grow more of it.
The cells are isolated in trays, fed nutrients and spread.
"They grow and divide, making a very thin sheet of about four to eight cells thick, across the bottom of flask we grow them in," said Dr. Jon Hopper, chief medical officer at Vericel Corporation.
Surgeons grafted the replicated skin Friday, a big step towards his recovery.
"He was already starting to grow his own skin on his own, but there was still a lot of his body without it," said Priscilla. "Afterward, when the doctors said he made it through, it was such a relief."
The lack of skin made it impossible to regulate his body temperature.
"Now, he doesn't have to have heat in the incubator, and his heart rate is around 120 beats per minute," said Priscilla. "Before he got here, it was over 200."
Another step forward is that doctors were able to open his eyelids, which were a thin membrane.
It was the first time his parents were able to look their son in the eyes.
"It's like a happy moment because we never got to see his eyes from the day he was born," said Priscilla.
Ja'bari now weighs just over 11 pounds, nearly triple his birth weight.
His parents have been with him every day, and he recognizes their voices and responds to them.
He can tell them apart from the sounds of the nurses and doctors.
As for the little boy's condition, what was once thought to be a rare skin disease is now turning into a deeper mystery.
Doctors at the Texas Children's Hospital say his original diagnosis in San Antonio was incorrect, and they are still working on further testing and may be naming it themselves.
"Whatever Ja'bari does have, it is a skin condition, we just don't know what it is," said Maldonado.
The family is still taking any donations as they live out of a Houston hotel room. You can help by following the link to their GoFundMe account.
Pioneer’s Mitchell overcomes long odds to get to CIF meet
(from commoncentsinvestor)
https://www.dailydemocrat.com/2019/05/23/pioneers-mitchell-overcomes-long-odds-to-get-to-cif-meet/
....
Two and a half years ago though, Mitchell and his family weren’t sure if he’d ever be able to jump three feet again let alone 23.
It was then that Mitchell dislocated his right shoulder in a youth football game in eighth grade. He tore his right labrum and a piece of cartilage was torn out of the socket.
The first doctor they saw said there was nothing that could be done.
“He initially was told the cartilage was inoperable and he’d not be able to play sports again,” Mitchell’s father Alan said.
The Mitchells met with a doctor at Shriners Hospital for Children in Sacramento though who got a grant to perform MACI (Matrix-induced Autologous Chondrocyte Implantation) surgery on Mason’s shoulder. MACI is a procedure that involves taking cartilage cells from one part of the body and growing them into a cartilage membrane to be re-implanted where the new cartilage cells will form repair tissue and fill the cartilage defect.
MACI is most commonly performed on knees but Mason’s surgery was the first time it was performed on a shoulder in the U.S. Doctors took cartilage from his knee, sent the cells to Boston where they were grown into a membrane over three months, and returned them to Shriners where Mason had surgery to repair his labrum and insert the new cells.
He was restricted to running only for 18 months and was only cleared for all sports in February. Mitchell’s first officially marked jump at the Honker Mini Invite on February 23rd, where he left with a best of 20'-1?, was his first competition mark in over two years.
.....
They were also on this TDA broadcast today. Missed it on twitter
I have a TDA account, so I don't know if everyone can see this
https://tdameritradenetwork.com/video/rB4AoWrUEe6BauDLyHAETQ
Nick Colangelo, CEO of @VericelCorp, gives an update on the company’s recent successes in an interview featured on @TDANetwork.
— Vericel® Corporation (@VericelCorp) May 23, 2019
Click the link below to watch and learn more: https://t.co/8MovXVbQWJ
right now they're looking for the bottom
something is afoot-
even in these presentations they're talking break even/incredible revenues/all nice stuff.
someone posted higher institutional holdings
Oppenheimer has PPS of 32ish
yet vcel is flailing down the time tunnel....
something must be afoot
Followers
|
139
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
8025
|
Created
|
11/08/03
|
Type
|
Free
|
Moderators |
Vericel Corporation. (VCEL)
http://epicel.com/healthcare-professionals/what-is-epicel/epicel-is-fda-approved/
https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/ucm543860.htm
Click on Yellow to REVIEW FDA WEBSITE APPROVING MACI
http://www.maci.com/
Interesting FDA Transcript discussions on MACI going forward for widened age bracket and other body joints.
CLICK ON THE ABOVE LINK
CLICK ON THE ABOVE PICTURE TO GO INTO VCEL'S CAREER'S SITE
IXMYELOCEL-T
Our preapproval stage portfolio includes ixmyelocel-T, a unique patient-specific multicellular therapy derived from an adult patient’s own bone marrow which utilizes our proprietary, highly automated and scalable manufacturing system. Our proprietary cell manufacturing process significantly expands the mesenchymal stromal cells (MSCs) and M2-like anti-inflammatory macrophages in the patient’s bone marrow mononuclear cells while retaining many of the hematopoietic cells. These cell types are known to regulate the immune response and play a key role in tissue repair and regeneration by resolving pathologic inflammation, promoting angiogenesis, and remodeling ischemic tissue. The novelty and advantage of using ixmyelocel-T is the expansion of a unique combination of cell populations, including MSCs and M2-like macrophages, which secrete a distinct combination of angiogenic and regenerative factors, and possess the ability to remain anti-inflammatory in the face of inflammatory challenge.
Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The company markets two cell therapy products in the United States. Carticel® (autologous cultured chondrocytes) is an autologous chondrocyte implant intended to treat cartilage defects in the knee in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing 2 additional cell products. MACI is a third generation autologous chondrocyte implant intended to treat cartilage defects in the knee. Ixmyelocel-T is a multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM).
Developing autologous (patient’s own) cell therapies—with integrity
Vericel uses rigorous scientific methods to develop novel therapies for the treatment of patients with autologous (patient’s own) cells. In addition, personal integrity, team work, collaboration, and innovative technology are the foundations of our work. We seek to practice transparency in our clinical trials and research, and in our relationships with each other, our patients, and the investors who support us.
Management:
http://vcel.com/about-vericel/#Management
Clinical Research:
http://vcel.com/research-and-development/#cardioMyopathy
Recent News:
http://investors.aastrom.com/releases.cfm
http://www.4-traders.com/VERICEL-CORP-18635051/
http://finance.yahoo.com/q/h?s=VCEL+Headlines
Events and Presentations:
http://investors.aastrom.com/events.cfm
Analyst Coverage:
http://investors.aastrom.com/analysts.cfm
http://www.streetinsider.com/Analyst+Comments/Vericel+(VCEL)+MACI+Approval+Puts+Profitability+Within+Reach+-+Needham+%26+Company/12343070.html
https://www.thecerbatgem.com/2016/12/19/needham-company-llc-analysts-give-vericel-corp-vcel-a-9-00-price-target.html
https://sportsperspectives.com/2016/12/22/piper-jaffray-cos-begins-coverage-on-vericel-corp-vcel.html
http://www.4-traders.com/VERICEL-CORP-18635051/consensus/
http://seekingalpha.com/symbol/VCEL
http://seekingalpha.com/article/1228921-is-takeda-interested-in-aastrom-bio
Filings:
http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0000887359&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany
Share Structure:
See Filings
http://data.cnbc.com/quotes/vcel
http://finance.yahoo.com/quote/VCEL/?p=VCEL
YOU TUBE VIDEOS, and the fourth video down, you will NOW appreciate the meaning of less invasive on the new FDA approved MACI procedure and why MACI is anticipated to be 20x the procedures of Carticel
https://www.youtube.com/watch?v=y3S1kFfT0Qk
https://www.youtube.com/watch?v=dP5TgnS3Vr4
https://www.youtube.com/watch?v=gCbpFoY6ZUM
https://www.youtube.com/watch?v=3MFL10O-avE MUST WATCH
http://wnyt.com/health/maci-new-procedure-to-repair-damaged-knee-cartilage/4369510/
https://www.dvidshub.net/news/223965/wbamc-employs-state-art-knee-implant-first-time-dod
Conference Calls
September 27, 2016 Ladenburg Thalmann
October 24, 2016 Meeting on the Mesa
November 30th, 2016 The 28th Annual Piper Jaffray Healthcare Conference
December 14th, 2016 Vericel Corporation Investor Call
Investor Relations:
http://investors.aastrom.com/index.cfm
Yummy Land, click on Above Picture
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn't a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |